Thousands of people who had never heard of the Pharmacy Compounding Advisory Committee a year ago marked their calendars for the PCAC meeting this week, anticipating actions that could transform how millions take charge of their health and clear the way for dramatic growth in peptide treatments.

That change, however, may not be as dramatic or immediate as many hope.

Let’s dive in.

A committee that critics have called burdened with peptide-friendly conflicts of interest will decide whether to recommend that the FDA allow compound pharmacies to dispense seven peptides, allowing practitioners to prescribe peptide powerhouses like BPC-157 and TB-500. Many of the people with the dates circled on their calendar anticipate a decision that opens the floodgates to legal access and a gold rush opportunity for compound pharmacists, doctors and peptide entrepreneurs.

Scott Brunner, who leads the Alliance for Pharmacy Compounding, has bad news for overly enthusiastic peptide practitioners, entrepreneurs and biohacking enthusiasts. There are no floodgates to easily open, and even if there were, availability of legally produced peptides will not suddenly look different on July 25 or whenever the Committee offers its recommendation.

The floodgate-free reality is complex. In 2023, the peptides were officially placed in Category 2 on the FDA’s 503A Bulk Drug Substances List, a move that barred compound pharmacies from manufacturing the substances. Health and Human Services Secretary Robert F. Kennedy Jr., however, declared support for peptides when he took office, and in April 2026, several of the most popular peptides were removed from Category 2, leaving them in regulatory limbo in advance of the PCAC meeting.

The path out of that limbo will likely remain unclear even if the Committee advises the FDA to move the peptides to Category 1, which normally allows compound pharmacies to dispense the ingredients. Insiders note that FDA staff scientists in early July released briefing documents firmly warning against easing access to the seven peptides in question, and a legal supply chain of human-grade peptides has not been established.

Rick Collins, a New York attorney whose client list includes peptide providers, advises entrepreneurs and others to keep their expectations tempered. The committee, which includes members appointed under Kennedy who have been criticized as too closely connected to the business of peptides, may recommend the FDA move the seven peptides in question to Category 1, but Collins points out that compound pharmacies could not immediately begin production for widespread physician prescribing. “There's a lot that would need to happen before this magical overnight transformation.”

Brunner sees formidable challenges, many of which would keep the peptides in a limbo state that may not closely resemble the one they’ve been trapped in since April, but in a limbo nonetheless. “I would expect, if they're going to be authorized, there's going to be some period of enforcement discretion because to formally add them to the list requires notice and comment rulemaking.”

Takeaway: The path out of that limbo will likely remain unclear even if the Committee advises the FDA to move the peptides to Category 1.

Peptide advocates say barring U.S. manufacturers and compound manufacturers from providing the peptides opened the door to sketchy foreign suppliers selling research-grade versions, which the FDA does not allow for human use. That means manufacturers operating legally would require time to ramp up production to supply compounding pharmacists with the peptides before they could begin filling prescriptions.

Brunner describes that as a major, if temporary, roadblock. “If we do have the finger snap, you're going to have prescribers suddenly shouting hallelujah and writing [prescriptions] for their patients. The patient's going to hop down to the compounding pharmacy, and the pharmacist is going to say, 'Sorry, I can't fill this, I can't acquire the active ingredient.'”

Robert Durkin, who represents peptide-engaged clients at Amin Wasserman Gurnani LLP, describes compound pharmacies as trapped in a difficult position. “They want the business. They want to compound. But they have to ensure the wholesomeness and quality of what they're compounding with. So, it's kind of a conundrum.”

Durkin says people eyeing careers in peptides have reason to be hopeful, but should not anticipate a smooth path to access. There are other powerful voices in the mix, he says. “Don't forget, a lot of these peptides are going to start competing with things that pharma has under investigation [for drug development]. This isn't something that pharma is crazy about either.”

Even if the PCAC recommends removing the prohibition on the peptides, compound pharmacies and prescribers will still need to follow state regulations, which govern both medical practice and compound pharmacy production and distribution. Durkin points to Alabama passing strict rules against peptide prescriptions and recommendations. Ohio stands out as a state that closely monitors compound pharmacies. While Durkin notes that “a lot of times the states will follow what FDA says,” there is no guarantee that practitioners will be able to practice peptide therapies or compound pharmacists be allowed to supply those peptides no matter what the Committee recommends and the FDA decides. “People have to realize that the practice of medicine and the practice of pharmacy are mostly regulated by the states,” Durkin explains.

That leaves prescribers eyeing the PCAC meeting with trepidation. Henry Legere, MD, who serves as chief medical officer for the Restore Hyper Wellness clinic chain, contends that clinics can’t support peptide use properly without clarity, and even if the Committee supports peptides, clarity could remain in short supply. He cites a “disconnect between the political message and the FDA scientific posture” that leaves responsible practitioners wary. “My expectation is that the committee may take a cautious approach, but I do not think anyone should assume the outcome is predetermined,” Legere says. “From the perspective of a clinic operator, this is not an abstract regulatory issue. Patients are already asking about peptides, already using peptides, and in many cases already sourcing them from gray-market labs where quality, sterility, identity, and dosing are not reliably regulated.”

Takeaway: Even if the PCAC recommends removing the prohibition on the peptides, compound pharmacies and prescribers will still need to follow state regulations, which govern both medical practice and compound pharmacy production and distribution.

Everybody interviewed for this story cited a similar dynamic. Peptides are already on the market and being used by mainstream consumers habituated to self-injecting peptides in GLP-1 drugs like Ozempic. “This is soccer moms and golf dads,” Collins explains, describing the ways those moms and dads are obtaining the peptides as often risky.

Such warnings are sure to be part of public comments during the two days of meetings. Opportunities for comment were already expanded beyond standard time allotments, but the Committee announced last week that Thursday’s meeting will stretch into evening hours.

A cautious approach for Collins would mean the FDA establishing a new framework for peptides that exists outside of the drug space and also separate from dietary supplements, something that could take time but would deliver the clarity compound pharmacists and practitioners like Legere are seeking. He points to the Dietary Supplement Health and Education Act as an example of how to give consumers safe access to products that would otherwise be pushed into the illicit. Similar regulations could be created for peptides. This new category, Collins says, “could be prescribed with certain caveats by a licensed healthcare provider, made subject to good manufacturing practices, produced with oversight and quality control, and delivered with heavy informed consent.” Collins said health claims would also need to be regulated and based on science, something often missing from how peptides are currently being used.

But Collins is quick to point out that dietary supplement regulations took time to be developed and even longer to be interpreted and clarified. “I think that is very much where we could go with this.”

Brunner also sees potential for regulators to build “guardrails” for peptide production and use that could include a structure like Collins describes. There is room for reform outside unencumbered access. “This should not be a binary choice,” he says, arguing that continuing an outright ban is unwise and makes public safety impossible to guarantee. “It's only a matter of time before there will be a serious patient adverse event or a series of patient adverse events resulting from folks who are going to chat rooms or bogus websites and acquiring these purported peptides without a prescription.”

Takeaway: The dates for the PCAC meeting are circled on thousands of calendars. The dates when peptide makers, users and practitioners will know what the meeting means for the future don’t yet exist on any calendar.

Pharmacist opposition Compound pharmacies may be advocating for safer access to peptides like BPC-157 and TB-500 now being considered by the Compounding Pharmacy Advisory Committee, but the American Pharmacists Association is not on board with granting the access. In a press release July 17, the APhA noted its opposition in comments the organization submitted to the committee.

Mainstream in the media Leading up to the PCAC, journalists are talking more about peptides and the trend is decidedly negative. Outlets like Healthline and Real Clear Health are going generically negative, while Politico dove deeper with a story focusing on illegal sales of retatrutide. How this plays out for consumers is unclear, but growth in peptide interest fueled by compounded GLP1 suggests little impact.

Pharmacists vs pharmacies The American Pharmacists Association of America is not following compound pharmacies on making peptides more accessible. In a press release last week, the APhA noted comments it submitted to the Compounding Pharmacy Advisory Committee that “pharmacists currently lack sufficient evidence to confidently counsel patients on many of the peptide substances under consideration.” According to the press release, the Association opposes adding the peptides to the Section 503A compounding list.

The pharma effect

Investor’s Business Daily explored what allowing public access to previously prohibited peptides being considered this week could mean for big pharma, noting that companies behind GLP1 blockbusters Ozempic and Wegovy are watching the situation closely and that the peptides could compete with both existing drugs and drugs in development. The story quoted American Peptide Association co-founder Jeff Chen saying, "The only reason why we're hearing about any of this is because it's competing with Lilly and Novo [Nordisk]."

The American Peptide Association offers cautious optimism

Q&A with Caitlin Koppenhaver, American Peptide Association

The peptide movement is moving quickly, and organizations are moving quickly too. The American Peptide Association was founded just last year and is engaging directly with the FDA on how peptides should be treated and what safety guardrails could look like if greater access is granted. We talked to the APA’s Chief Industry Advisor Caitlin Koppenhaver about what the Association expects from the Compounding Pharmacy Advisory Committee meetings.

What are you telling members about what to expect from the Pharmacy Compounding Advisory Committee meeting? 

The public should understand that the PCAC’s review and recommendation are advisory. The FDA will ultimately make the final determination as to whether any of the seven APIs will be added to the 503A Bulks List. Nevertheless, the meeting provides an important opportunity to place public comments, real-world experience and the consequences of exclusion before the Committee as it develops its recommendation.

What do you hope for at the meeting? 

The American Peptide Association hopes for a fair and substantive discussion that recognizes the significant consumer demand for these substances, the real-world experiences reported by patients and practitioners and the limitations of applying a traditional pharmaceutical safety-and-efficacy framework to nonproprietary peptides. Even if the Committee is not prepared to recommend inclusion, the APA hopes the meeting will create a meaningful public record demonstrating the need for an alternative regulatory pathway that preserves safety, quality, transparency and responsible access. The APA therefore hopes that, whether through inclusion supported by appropriate safeguards or through development of an alternative regulatory pathway, the FDA will provide meaningful regulatory direction rather than leaving patients, practitioners and industry participants without a workable framework.

What do you expect will happen at the meeting?

We do not know how the Committee will vote. It may agree with the FDA, disagree as to some or all of the substances, or reach mixed conclusions. It is also important for the public to remember that the Committee is not evaluating whether these peptides are appropriate or beneficial in the abstract. Each substance is being evaluated narrowly under the statutory 503A criteria and in connection with the specific proposed use or uses presented to the Committee.
Regardless of the vote, the PCAC’s recommendation is advisory, and the ultimate determination remains with the FDA. The FDA may consider the Committee’s recommendation but is not required to follow it.  The FDA’s own briefing materials state that it will not make a final determination until the advisory-committee input has been considered and its reviews are complete, and that the final determination may be affected by matters not discussed during the meeting. Prior PCAC proceedings have likewise shown that even a favorable Committee recommendation does not, by itself, result in a substance being added to the 503A Bulks List. For example, in 2022, the Committee voted 8–5 in favor of adding glutathione despite the FDA’s recommendation against inclusion, but the vote did not itself add glutathione to the final list. PCAC-20220608-Minutes.pdf

In the interim, however, these substances remain in a form of regulatory purgatory: they are still under evaluation, remain outside the Category 1 enforcement-discretion framework, and lack a final determination as to whether they may be used under Section 503A. If the FDA ultimately declines to add the substances to the 503A Bulks List, they would no longer remain in that interim position, rather, the traditional 503A pathway would effectively be foreclosed, absent another statutory basis for compounding. The APA’s concern is that either prolonged uncertainty or outright exclusion may leave patients and practitioners without a workable regulated pathway while doing little to address the underlying demand.

How has the APA engaged with the committee and FDA regulator in regards to the meeting?

The APA submitted a written position statement to the PCAC docket presenting a candid counter-perspective to FDA’s proposed exclusion of the seven substances. The APA also called upon its membership and broader community to provide available data, case histories and real-world experiences concerning their use. Through its written submission and anticipated participation in the public-comment process, the APA has emphasized both the limitations of the current framework and its willingness to work with FDA on a clearer pathway centered on safety, quality, testing transparency and responsible access.

What kind of engagement with the FDA do you anticipate if the Committee advises moving the peptides to Category 1?

The APA would anticipate continued engagement with FDA regarding the evidence necessary for further evaluation and the development of workable safeguards, including appropriate quality standards, independent testing, adverse-event reporting, supply-chain transparency and responsible clinical oversight. The APA’s objective would be to help translate a favorable recommendation into a durable and administrable pathway rather than treating the Committee’s recommendation as the end of the process.

Are you encouraged by committee members appointed under Robert F Kennedy Jr?

The APA is encouraged by any indication that Committee members may be willing to examine the real-world consequences of the existing regulatory framework and consider perspectives outside the conventional pharmaceutical model. At the same time, the APA’s position should not depend on who appointed an individual member or presume how that individual member will vote. The APA hopes all Committee members will approach the evidence independently, recognize the limitations of the current framework identified in our submission and remain open to regulatory approaches that protect both public safety and meaningful access.

Practitioners must be cautious not to jump the gun on peptides

Q&A with Karthik Achari PepMD

Karthik Achari is a clinician and founder of PepMD, an organization supplying standards and credentials to practitioners subscribing peptides and working with patients to create peptide protocols. We talked to him about the upcoming meeting of the Compounding Pharmacy Advisory Committee and what it could mean to pracitioners.

What do you think is going to happen at the committee meeting?

I won't predict the vote, it's genuinely the committee's call and smart people land on both sides. The FDA's own briefing documents came out against adding all seven, and there's a well-funded push the other way, so it's a real contest. But the vote isn't the thing I'd watch. Whichever way it goes, it only decides whether a licensed pharmacy can legally compound these. It doesn't touch who's prescribing them, how they're sourced, or whether anyone's tracking what happens to patients. It settles less than people think.

How closely are practitioners watching this?

Very closely, because their ability to practice depends on it. If you've built part of your practice around these compounds, you're watching to find out whether your supply becomes legal or disappears. What I'd note is that most people are watching the yes-or-no. Far fewer are asking what they'll actually need in place the day after, whichever way it goes.

Where are they turning for information?

A little bit of everywhere, which is the problem. Social media, podcasts, peptide education programs, pharmacy communications, each other. There's real education being built for this space now and some of it is genuinely good. But there's no single place that tells a practitioner what qualified practice actually looks like, so they piece it together from wherever they can find it. And when everyone's building their own practice patterns from different sources, you get wide variation in how the same peptide gets used.

If the committee recommends the peptides be approved for compound pharmacy manufacture, what do you think practitioners should do?

Treat it as a start, not a finish. Approval would make the supply legal. It wouldn't make the practitioner prepared. Before anyone scales up prescribing, the training, the sourcing verification, the monitoring all have to actually be in place. And this is the part I'd want practitioners to hear: standards don't have to slow any of this down. They mostly just make it repeatable, so the next clinician isn't starting from scratch and the patient isn't depending on which practitioner they happened to find.

Is there a possibility practitioners could read more into that approval than is warranted, possibly assuming peptides to be suddenly legal?

Yeah, and it's a real risk. Getting added to the 503A bulks list means a licensed compounding pharmacy can prepare these under specific conditions. It doesn't make them FDA-approved drugs, it doesn't legitimize the grey market, and it doesn't mean anything goes. The worry is that a headline like “FDA approves peptides” gets read as blanket permission when the actual decision is narrow and technical. Clear standards are part of how you keep that from happening.

If there is approval, do you anticipate a rush of practitioners coming in to explore the space?

Almost certainly. Remove a legal barrier, send that signal, and with demand already this high, you'd see a wave of new prescribers. And that's the part that worries me if the infrastructure isn't ready. A rush of practitioners into a space with no credentialing standard, no consistent training requirement, and nobody tracking outcomes is how quality problems happen at scale. The practitioners are coming either way. The question is whether the standard is there before the scale is.

The question is how consumers can access them safely

By Dr. Henry Legere, Chief Medical Officer at Restore Hyper Wellness

I am watching the July 23–24 PCAC meeting very closely because it could shape the next chapter of physician-directed peptide access in the United States. From the perspective of a clinic operator, this is not an abstract regulatory issue. Patients are already asking about peptides, already using peptides, and in many cases already sourcing them from gray-market labs where quality, sterility, identity, and dosing are not reliably regulated.

The most interesting part of this meeting is the disconnect between the political message and the FDA scientific posture. Secretary RFK Jr. has publicly suggested, including on Joe Rogan, that peptides could become commercially available again soon. That created real optimism in the wellness, longevity, and compounding communities. But the FDA briefing materials prepared ahead of the PCAC meeting appear to send the opposite signal. FDA staff have expressed skepticism about adding the reviewed peptides to the 503A Bulks List, citing limited evidence and safety concerns. The July meeting will review BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon for possible inclusion on the 503A Bulks List.

Historically, PCAC often follows the FDA scientific staff’s recommendations, but it is unclear whether that will happen this time. There is unusual public attention, political pressure, and patient demand around this issue. My expectation is that the committee may take a cautious approach, but I do not think anyone should assume the outcome is predetermined.

I’m personally involved with Restore Hyper Wellness, JRNYS, Kinsyn and other health and wellness brands which will be impacted by this decision and central issue is whether the FDA allows a regulated pathway for physician-directed access. If these peptides are not added to the 503A Bulks List, legitimate operators will remain constrained, while consumer demand will not disappear. That creates a problematic public-health outcome: patients may continue buying peptides online from gray-market sources without meaningful quality control or medical oversight.

The policy question is not whether peptides are already being used. They are. The better question is whether we want that use to occur through unregulated internet labs or through state-regulated 503A pharmacies, with prescriptions, informed consent, adverse-event monitoring, clinician oversight, and real-world data collection. I do not believe every peptide should be treated as proven, risk-free, or appropriate for broad use. But I do believe a blanket prohibition can drive patients into less safe channels.

For responsible clinic operators, the path forward should be conservative, transparent, and data-driven: only use lawful products, avoid overstated claims, monitor outcomes, educate patients honestly about uncertainty, and advocate for a regulatory framework that balances safety with access. Peptides are out of the bag. The question now is whether regulators, physicians, and responsible companies can create a safer framework than the gray market patients are already using.